Abbott achieved a favorable procedural outcome, broad discovery expansion was denied and the case is on track for summary judgment resolution within weeks. The company's denial of the plaintiffs' request to reopen discovery limits the scope of evidence plaintiffs can use, reducing settlement leverage. Monitor the supplemental briefing due May 19 and June 2, 2026 for the court's summary judgment ruling. A grant of summary judgment would remove the case entirely; a denial would set up trial and materially increase ABT's liability exposure.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 23 $91.26entry
- T+1 · 7mo ago −1.46%α −2.23% · $89.93
- T+5 · 7mo ago −1.83%α −3.27% · $89.60
- T+20 · 6mo ago −5.09%α −9.93% · $86.62
- T+60 · 4mo ago +8.54%α +2.65% · $99.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The court denied plaintiffs' motion for sanctions against Abbott and denied their request to reopen discovery in this infant formula product liability case. The court granted only limited post-discovery production of Abbott's written response to the FDA's 2022 Establishment Inspection Report and a brief supplemental briefing schedule on Abbott's pending summary judgment motion. The ruling is a modest procedural win for Abbott: the case remains alive but plaintiffs were denied the broad discovery expansion they sought, and the core summary judgment motion is still pending with near-term resolution likely.
Court Ruling Details
Key Facts
- Plaintiffs' motion for sanctions against Abbott was DENIED for failure to follow local court rules
- Plaintiffs' request to reopen discovery for six months was DENIED
- Court ordered Abbott to produce its written response to the FDA's 2022 EIR by May 5, 2026
- Abbott's summary judgment motion is stayed for supplemental briefing; decision still pending
- Case is a product liability suit alleging infant formula contamination with Cronobacter sakazakii, filed September 2023
- Dismissal of a parallel FCA lawsuit (Millard) was unsealed November 2025; plaintiffs' two-month delay in seeking to use it weighed against reopening discovery
- No damages awarded or estimated in this order, it is a procedural ruling on discovery and scheduling
Financial Impact
No financial award or estimate in this ruling. This is a procedural/interlocutory order, no damages determined. The case has no stated financial exposure figure in the document.
Risk Factors
- If summary judgment is denied, the case proceeds to trial with product liability allegations still pending
- FDA 2022 EIR production (ordered by May 5) could produce damaging documents
- Underlying Cronobacter contamination allegations could attract additional lawsuits or regulatory scrutiny even if this case is resolved favorably
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-332r7b1d-ABT |
Track record
38 reports on ABT
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +17.16% at T+20 after the Jul 1, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $109.93 Now $107.45 −2.26% settles Dec 7
- Oct 27, 202620d ago ANALYST-DOWNGRADE Neutral 2/10 Entry $103.10 Now $107.45 +4.22% settles Nov 24
- Oct 27, 202621d ago Court Ruling Neutral 1/10 Entry $102.64 Now $107.45 +4.69% settles Nov 25
- Oct 21, 202626d ago Institutional Cluster Mixed 4/10 Entry $102.51 Now $107.45 +4.82% settles Nov 19
- Oct 21, 202626d ago 8-K Bullish 6/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
- Oct 21, 202626d ago 8-K Bearish 6/10 No price data
- Oct 21, 202626d ago Press Release Neutral 4/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
- Oct 20, 202628d ago Court Ruling Neutral 1/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
- Oct 16, 20264w ago Court Ruling Neutral 2/10 Entry $104.06 to $107.45 Now $107.45 +3.26% ▲ +3.26% +6.72% vs SPY
- Oct 15, 20264w ago Court Ruling Bullish 5/10 Entry $104.89 to $108.52 Now $107.45 +2.44% ▲ +3.46% +4.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers